New drug targets tough cancers in early trial
NCT ID NCT06616766
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called YH42946 in people with advanced solid tumors that have certain gene changes (HER2 or EGFR). The main goals are to check safety and see if the drug shrinks tumors. About 161 adults who have run out of standard options will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC (NON-SMALL CELL LUNG CANCER) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Asan Medical Center, University of Ulsan
RECRUITINGSeoul, South Korea
-
Chungbuk National University Hospital
RECRUITINGCheongju-si, North Chungcheong, 28644, South Korea
-
Next Oncology Virginia
RECRUITINGFairfax, Virginia, 22031, United States
-
Samsung Medical Center
RECRUITINGSeoul, 06351, South Korea
-
Seoul National University Bundang Hospital
RECRUITINGSeongnam-si, Gyeonggi-do, 13620, South Korea
-
Seoul National University Hospital
RECRUITINGSeoul, 03080, South Korea
-
Severance Hospital, Yonsei University
RECRUITINGSeoul, 03722, South Korea
-
The Catholic Univ. of Korea St. Vincent's Hospital
RECRUITINGSuwon, Gyeonggi-do, 16247, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shield nerves from Chemotherapy's side effects?
- Can a Tumor's DNA guide better cancer care for kids?
- Can a new immune drug outsmart Hard-to-Treat tumors?
- Can a new PET tracer reveal a key cancer target?
- Can a smart drug home in on Hard-to-Treat cancers?
- Can a pill plus immunotherapy and targeted radiation shrink lung tumors before surgery?